Preliminary clinical study on probiotics Bacteroides fragilis BF839 and Dragon protein in the treatment of Parkinson

Preliminary clinical study on probiotics Bacteroides fragilis BF839 and Dragon protein in the treatment of senile dementia

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000035122

Enrollment

Unknown

Registered

2020-08-01

Start date

2020-08-01

Completion date

Unknown

Last updated

2022-01-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson

Interventions

Intervention group:probiotics Bacteroides fragilis BF839 and Dragon protein

Control group:Placebo

Eligibility

Sex/Gender

All

Age

40 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged 40-75 years. 2. Patients who meet the diagnosis of Parkinson's disease based on clinical symptoms and Parkinson's Unified Scale Score. 3. The patient's eating is not significantly affected by the disease and can eat independently. 4. The original Parkinson's drug has been used stably for more than 2 weeks.

Exclusion criteria

Exclusion criteria: 1. Accepted other clinical trials within one month; 2. Inability to eat independently; 3. Patients with severe heart, liver, and kidney insufficiency, and critical illness; 4. Cancer patients; 5. Have obvious protein food allergies; 6. He received new Parkinson's medication 2 weeks before enrollment; 7. Use of probiotic drugs or food before enrollment.

Design outcomes

Primary

Measure	Time frame
Scale score;	—

Countries

China

Contacts

Public ContactDeng Yuhong

The Second Affiliated Hospital of Guangzhou Medical University

1376708863@qq.com+86 20 24152843

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 5, 2026